Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort
Abdul Rafeh Naqash(Oklahoma City University), Paul R. Walker(East Carolina University), Rita Chiari(Azienda Ospedaliera di Perugia), Biagio Ricciuti(Harvard University), Wungki Park(University of Miami), Mahvish Muzaffar(East Carolina University), Vaia Florou(University of Utah), Gilberto Lopes(University of Miami), Shunichi Sugawara(Sendai Kousei Hospital), Andrea De Giglio(Azienda USL di Bologna), Dwight H. Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Yukihiro Toi(Sendai Kousei Hospital), Sandip H. Patel(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jarred Burkart(The Ohio State University), Cynthia R. Cherry(East Carolina University), Gregory A. Otterson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Maida Hafiz(East Carolina University), Jun Sugisaka(Sendai Kousei Hospital)
Cited by 97
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k